Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 31, 2026 (Event Date: August 30, 2026)
Context: BioMarin entered into a binding term sheet with Ascendis Pharma A/S to resolve all pending litigation regarding BioMarin Patent Rights related to the C-type natriuretic peptide "TransCon CNP" (navepegritide/Yuviwel).
Key Financial Metrics and Transaction Terms
This filing details a settlement and license agreement rather than periodic financial results. Key financial terms include:
- Royalty Structure: Ascendis will pay BioMarin a royalty on annual net sales of Licensed Products.
- United States Rate: 20% of annual net sales.
- International Rate: 18% of annual net sales in the European Union, Brazil, and South Korea.
- Duration: Royalties apply from the date of first commercial sale (retroactively, as applicable) until May 2030.
- Liquidity/Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Litigation Resolution
The primary material change is the resolution of legal disputes and the establishment of a new revenue stream:
- Litigation Dismissal: All pending litigation between BioMarin and Ascendis relating to the BioMarin Patent Rights will be dismissed with prejudice.
- License Grant: BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to research, develop, manufacture, use, sell, and commercialize Licensed Products for all indications, including achondroplasia and hypochondroplasia.
- Legal Covenants: Includes a mutual regulatory non-interference clause, a covenant by Ascendis not to challenge BioMarin's Patent Rights, and a release of prior infringement claims.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The company anticipates benefits from the transaction, including royalty payments and the dismissal of legal proceedings. The parties agreed to negotiate in good faith to execute a definitive Agreement by September 24, 2026. If not executed by this date, the Term Sheet provisions remain binding.
Risks and Contingencies: Forward-looking statements involve risks, including:
- BioMarin's ability to enforce the Term Sheet or the final Agreement.
- Actual sales volumes of the Licensed Products.
- General risk factors detailed in BioMarin's Form 10-Q for the quarter ended June 30, 2026.
Investor Verification Checklist
- Verify the execution of the definitive Agreement by the September 24, 2026 deadline.
- Monitor the commercial launch dates of navepegritide (Yuviwel) to determine the start of royalty accruals.
- Review the definition of "net sales" in the final Agreement to understand royalty calculation mechanics.
- Confirm the formal dismissal of all pending litigation in relevant jurisdictions.
- Assess the impact of the 2030 expiration date on long-term revenue projections.